Edition:
United States

Entellus Medical Inc (ENTL.OQ)

ENTL.OQ on NASDAQ Stock Exchange Global Market

24.35USD
8 Dec 2017
Change (% chg)

$0.36 (+1.50%)
Prev Close
$23.99
Open
$23.94
Day's High
$24.40
Day's Low
$23.88
Volume
325,411
Avg. Vol
58,173
52-wk High
$24.40
52-wk Low
$11.48

Summary

Name Age Since Current Position

Brian Farley

59 2016 Non-Executive Chairman of the Board

Robert White

55 2015 President, Chief Executive Officer, Director

Brent Moen

49 2016 Chief Financial Officer, Corporate Secretary

Michael Rosenthal

43 2017 Chief Operating Officer

Jonelle Burnham

46 2017 Chief Compliance Officer, Vice President, General Counsel

Stephen Paidosh

54 2007 Vice President, Operations

Thomas Williamson

42 2017 Vice President - Sales

Kevin Mensink

44 2013 Vice President of Marketing

Martha Christian

53 2017 Vice President, Reimbursement

Timothy Petrick

49 2008 Vice President, Research and Development

James Momtazee

45 2017 Director

Douglas Rohlen

49 2017 Director

John Bakewell

55 2015 Independent Director

Joshua Baltzell

47 2006 Independent Director

Shawn McCormick

52 2014 Independent Director

David Milne

54 2006 Independent Director

Guido Neels

68 2009 Independent Director

Biographies

Name Description

Brian Farley

Mr. Brian E. Farley is Non-Executive Chairman of the Board of the Company. He also served as our President from March 2010 to November 2014 and as our Chief Executive Officer from March 2010 to April 2015. Prior to joining us, Mr. Farley was employed at VNUS Medical Technologies, Inc. starting in 1995 and served as President and Chief Executive Officer of VNUS from January 1996 to June 2009 when VNUS was sold to Covidien Ltd. Prior to joining VNUS, Mr. Farley was employed from 1981 to 1995 at Guidant Corporation, in the Medical Device Division of Eli Lilly and Company, and in Lilly Research Labs in a variety of research and development, clinical research and business development leadership positions. Since November 2009, Mr. Farley has served as a director of Neuronetics, Inc., a private medical device company, including as Chairman of the Board from June 2011 to July 2014 and again since December 2014. Mr. Farley has also served on the board of directors of DFINE, Inc., a private medical device company, as well as its compensation committee, since March 2012. Mr. Farley holds both a B.S. in Engineering with an emphasis in Biomedical Engineering and an M.S. in Electrical Engineering from Purdue University.

Robert White

Mr. Robert S. White is President, Chief Executive Officer, Director of the Company. Mr. White first joined Entellus Medical as our President and Chief Operating Officer in November 2014. Mr. White previously was the President and Chief Executive Officer of TYRX, Inc., or TYRX, which specialized in commercializing innovative, implantable combination drug and device products focused on infection control, from January 2010 to March 2014, when TRYX was sold to Medtronic. Prior to joining TYRX, Mr. White held several positions with Medtronic from February 2003 to November 2009, including serving as President of Medtronic Kyphon from April 2008 to August 2009 following the acquisition of Kyphon by Medtronic. Mr. White started his career with General Electric and joined Eli Lilly and Company in 1989. Mr. White serves on the boards of directors of several companies, including publicly traded companies Novadaq Technologies (September 2014 to present) and AtriCure, Inc. (March 2013 to present), as well as HyperBranch Medical Technology, Inc. (June 2010 to present). Mr. White holds a B.S. in Aerospace Engineering from the University of Missouri-Rolla and an M.B.A. from Cornell University’s Johnson Graduate School of Management.

Brent Moen

Mr. Brent A Moen is Chief Financial Officer, Corporate Secretary of the Company. He has more than 25 years of financial experience. Previously he served as Executive Vice President and Chief Financial Officer of ABRA Auto Body & Glass. During his tenure at ABRA, Mr. Moen was responsible for the company's overall financial strategy including business development and raising capital. Prior to his role at ABRA Auto Body & Glass, Mr. Moen served as Senior Vice President and Chief Financial Officer of Regis Corporation, a publicly traded company that owns, operates and franchises more than 9,500 hair salons in the United States and Internationally. Mr. Moen received his bachelor's degree in accounting from the University of North Dakota and is a Certified Public Accountant (current status inactive).

Michael Rosenthal

Mr. Michael H. Rosenthal is Chief Operating Officer of the company. He currently serves as General Manager, a position he has served since July 13, 2017, when Entellus acquired Spirox, Inc., a medical device company. From May 2015 to July 2017, Mr. Rosenthal served as Chief Strategic and Technology Officer of Spirox, Inc. From December 2012 to May 2015, Mr. Rosenthal served as General Partner of D3DC, LLC, a medical device management company. Mr. Rosenthal holds a B.S. in Mechanical Engineering from Stanford University.

Jonelle Burnham

Ms. Jonelle R. Burnham is Chief Compliance Officer, Vice President, General Counsel of the Company. Ms. Burnham has extensive experience as a corporate attorney in highly competitive and regulated industries for global enterprises engaged in manufacturing and distribution. Prior to joining Entellus in February of 2016, she served as Vice President, General Counsel and Secretary of Patterson Companies, a full service distributor to specialty markets, and before that, was a member of the legal team at Kimberly-Clark Corporation, where she counseled its North American Consumer Products sales team, among other roles. Ms. Burnham began her career as a litigation attorney with the Minneapolis law firm of Merchant & Gould. She also serves on the board of directors of Living Well Disabilities Services, a Minnesota-based nonprofit.

Stephen Paidosh

Mr. Stephen Paidosh is Vice President, Operations of the Company. From July 1999 to December 2007, Mr. Paidosh served as Vice President of Operations at Myocor, Inc., a privately held medical device company. From December 1988 to July 1999, Mr. Paidosh held various leadership positions in engineering and operations at SCIMED Life Systems, Inc., and at Boston Scientific Corporation following the acquisition of SCIMED by Boston Scientific, ending as Director of International Vascular and Metallurgical Operations. Prior to that, Mr. Paidosh held positions in engineering with Pfizer Inc.’s subsidiary Schneider-Shiley (USA) Inc. and at St. Jude Medical, Inc. Mr. Paidosh holds a B.S. in Industrial Technology (Manufacturing Engineering) from the University of Wisconsin, Stout.

Thomas Williamson

Mr. Thomas D. Williamson is Vice President - Sales of the Company. Over his five years with Entellus, Mr. Williamson has been a consistent top producing sales executive with substantial selling and managing experience and a proven track record of territory development, sales growth and team leadership. He has hired and trained over 30 sales representatives, developed and promoted six District Sales Managers and created a new Strategic Account Management role at Entellus. Immediately prior to joining Entellus, Mr. Williamson worked for Stryker Corporation, most recently as National Sales Director for the Interventional Spine Division.

Kevin Mensink

Mr. Kevin L. Mensink is Vice President of Marketing of the Company. From January 2007 to March 2013, Mr. Mensink served as Vice President of Marketing for GN ReSound Group, a division of GN Store Nord A/S, a Danish corporation, where he was responsible for North America marketing, product management and technical support and training. From October 2005 to January 2007, Mr. Mensink served as Director of Marketing Analytics for GN ReSound Corp. From May 2002 to October 2005, Mr. Mensink served as Marketing Manager at Thomson West in the Corporate Segment Division. Prior to that, Mr. Mensink served as a Senior Financial Analyst at Thomson West from October 1997 to May 2002. Mr. Mensink holds a B.S. in Business Administration, Accounting and Economics and an M.B.A. in Management from the University of St. Thomas.

Martha Christian

Ms. Martha J. Christian is Vice President, Reimbursement of the Company. From March 2015 to February 2017, Ms. Christian served as President of Manitou Hill Solutions LLC, a company providing strategic reimbursement consulting services to the medical device industry. From June 2014 to January 2015, she served as Director of US Reimbursement at Coloplast Corporation, a Danish company specializing in urology and ostomy products. From April 2001 to April 2014, Ms. Christian served as Director of Strategic Reimbursement at Princeton Reimbursement Group, a corporate medical device reimbursement consulting firm. Over the years as a reimbursement consultant, Ms. Christian has worked with a broad range of products throughout the product life cycle to facilitate successful market adoption and expansion. Ms. Christian began her career as a health facility administrator before entering the medical device industry. Ms. Christian holds a M.S. in Continuing Studies from Minnesota State University, Mankato and a B.S. in Political Science from St. Olaf College.

Timothy Petrick

Mr. Timothy B. Petrick is Vice President, Research and Development of the Company. He has served in the capacity of Manager or Director of Research and Development from February 2007 to May 2008. From October 2002 to December 2006, Mr. Petrick was a Project Engineer with Velocimed, Inc. which was acquired by St. Jude Medical, Inc. in 2005. From January 1998 to July 2002, Mr. Petrick held various positions in regulatory affairs and engineering with TERAMed Corporation, which was acquired by Cordis Corporation, a division of Johnson & Johnson, in 2001. Mr. Petrick holds a B.S. in Mechanical Engineering from North Dakota State University.

James Momtazee

Mr. James C. Momtazee serves as Director of the company. He is a Member of KKR Management LLC, the general partner of KKR & Co. L.P. (together with its subsidiaries, “KKR”), and Head of the Americas Health Care industry team within KKR’s Private Equity platform. He also serves on the board of directors of PRA Health Sciences, Inc., a publicly held company. He previously served on the boards of directors of Jazz Pharmaceuticals plc from 2004 to 2014, HCA Holdings Inc. from 2006 to 2014 and Lake Region Medical from 2005 to 2015. Prior to joining KKR, Mr. Momtazee was with Donaldson, Lufkin & Jenrette. He holds an A.B. from Stanford University and an M.B.A. from Stanford University Graduate School of Business.

Douglas Rohlen

Mr. Douglas S. Rohlen serves as Director of the company. He served as President and Chief Executive Officer of Spirox, Inc. from February 2013 until Spirox was acquired by Entellus on July 13, 2017. Mr. Rohlen serves as Chief Executive Officer of Ajax Health LLC, a company that invests in and operates health care companies, a position he has held since April 2017. Mr. Rohlen also serves as Chief Executive Officer of Advanced Cardiac Therapeutics, Inc., a company focused on treating cardiac arrhythmias, a position he has held since April 2014. From January 2009 to January 2013, Mr. Rohlen served as Chief Executive Officer and founder of CV Ingenuity Corp., a company acquired by Covidien plc that developed devices for the treatment of vascular diseases to relieve vascular obstructions, inhibit restenosis, and allow natural vessel healing. From January 2006 until October 2007, Mr. Rohlen served as President of Strategic Operations of FoxHollow Technologies, Inc., a company acquired by ev3 Inc. that developed products for the treatment of peripheral artery disease, or PAD, and other cardiovascular disease, and from May 2004 to December 2005, Mr. Rohlen served as FoxHollow’s Vice President of Corporate Development and Investor Relations and as Director of Business Development. From 2001 to 2004, Mr. Rohlen served as President and Chief Executive Officer of Olive Hill Development, a land development company. From 2000 to 2001, Mr. Rohlen served as a project consultant at Massachusetts General Hospital. From 1999 to 2000, Mr. Rohlen held the position of Director of Business Development at LuMend Corporation, a privately-held company that develops chronic total occlusion products in the treatment of peripheral vascular disease which was acquired by Cordis Corporation. In 1999, Mr. Rohlen served as Entrepreneur in Residence at Alta Partners, a venture capital firm. Mr. Rohlen holds a B.A. in History from Stanford University and an M.B.A. from Harvard Business School.

John Bakewell

Mr. John K. Bakewell is Independent Director of the Company. Mr. Bakewell has served as the Chief Financial Officer of Exact Sciences Corporation since January 2016. Mr. Bakewell previously served as the Chief Financial Officer of Lantheus Holdings, Inc. from July 2014 to December 2015, as the Chief Financial Officer of Interline Brands, Inc. from June 2013 to May 2014 and as the Executive Vice President and Chief Financial Officer of RegionalCare Hospital Partners from January 2010 to December 2011. In addition, Mr. Bakewell held the position of Chief Financial Officer with Wright Medical Group from 2000 to 2009, with Altra Energy Technologies from 1998 to 2000, with Cyberonics, Inc. from 1993 to 1998 and with Zeos International from 1998 to 2000. Since July 2008, Mr. Bakewell has served on the board of directors of Keystone Dental, Inc., a private medical device company, where he also serves as chair of the audit committee, and from April 2006 to July 2010, served on the board of ev3, Inc., which was a publicly traded medical device company until it was acquired by Covidien plc in 2010. He also served as chair of the audit committee and as a member of the nominating and corporate governance committee for ev3. Mr. Bakewell holds a Bachelor of Arts in Accounting from the University of Northern Iowa and is a certified public accountant (inactive).

Joshua Baltzell

Mr. Joshua J. Baltzell is Independent Director of the Company. Mr. Baltzell is a Venture Partner at Split Rock Partners, LLC and also serves as a Venture Partner at SightLine Partners LLC. He has been with Split Rock Partners, LLC, since May 2004 and with SightLine since July 2014. Mr. Baltzell has over 20 years of experience in the healthcare industry. Prior to his tenure in the venture capital industry, Mr. Baltzell held roles as an investment banker at Piper Jaffray Companies from 2000 to 2002, where he focused primarily on mergers and acquisitions in the medical device sector, as well as various marketing and business development positions with SCIMED and Boston Scientific. Mr. Baltzell currently serves on the boards of Colorescience, EBR Systems, Inc., and DFINE, Inc., all privately held companies, and of Histogenics Corporation a publically traded medical technology company where he also serves on both the compensation and corporate governance and nominating committees. From August 2011 to July 2015, he also served on the board of directors of RF Surgical Systems, Inc. Mr. Baltzell holds a B.A. in Economics from St. Olaf College and an M.B.A. from the University of Minnesota’s Carlson School of Management.

Shawn McCormick

Mr. Shawn T. McCormick CPA., is Independent Director of the Company. Mr. McCormick served as Chief Financial Officer of Tornier N.V. and Tornier, Inc. and as Tornier’s Principal Accounting Officer from September 2012 until October 2015 when Tornier merged with Wright Medical. Before that, Mr. McCormick served as Chief Operating Officer of Lutonix Inc. from April 2011 to February 2012 and as Chief Financial Officer and Senior Vice President of ev3, Inc. from January 2009 to July 2010. He served as Vice President of Corporate Development at Medtronic, Inc. from May 2008 to January 2009, where he was responsible to lead its worldwide business development activities and served in key corporate and divisional financial leadership roles within the Medtronic organization. He has been a member of the board of directors of Nevro Corp. since September 2014 and serves as chairman of the audit committee. He has also been a director of Surmodics, Inc. since December 2015 and serves on the audit committee and the corporate governance and nominating committee. Mr. McCormick previously served on the board of LANX from August 2010 to November 2013, serving on the compensation committee and audit committee, before LANX was sold to Biomet in November 2013. Mr. McCormick is a certified public accountant and holds a B.S. in Accounting/Finance from Arizona State University and an M.B.A. from the University of Minnesota’s Carlson School of Management.

David Milne

Mr. David B. Milne is Independent Director of the Company. Mr. Milne is a Managing Partner at SV Life Sciences Advisers, LLC, or SVLS. He joined SVLS in 2005 and has 25 years of experience in the healthcare industry, having worked at several leading public and private medical technology companies. From 1999 until joining SVLS in 2005, he held the position of Vice President of Corporate Business Development at Boston Scientific. Mr. Milne currently sits on the board of Altura Medical, Inc., EBR Systems, Inc., ReShape Medical, Inc., and Spinal Kinetics, Inc., all privately held companies, and TransEnterix, Inc., a publicly traded medical device company, where he also serves on the corporate governance and nominating committee. In addition, Mr. Milne previously served on the board of AqueSys, Inc., Sadra Medical, Inc., MindFrame, Inc., NovaLign, Inc. and CardioMind, Inc., all privately held companies. Previously Mr. Milne worked at SCIMED, Becton, Dickinson and Company and Parker Laboratories, Inc. He holds a B.S. in Biology from Rutgers University and an M.B.A. in Marketing/Finance from New York University.

Guido Neels

Mr. Guido Neels is Independent Director of the Company. Mr. Neels has been with Essex Woodlands Health Ventures, or Essex Woodlands, a private equity investment firm, since 2006, where he is an Operating Partner. Prior to joining Essex Woodlands, Mr. Neels served in a variety of management positions at Guidant Corporation, a developer of cardiovascular medical products. From July 2004 until retiring in November 2005, Mr. Neels served as Guidant’s Chief Operating Officer, where he was responsible for the global operations of Guidant’s four operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery and Endovascular Solutions. From December 2002 to July 2004, Mr. Neels served as Guidant’s Group Chairman, Office of the President, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. In January 2000, Mr. Neels was named Guidant’s President, Europe, Middle East, Africa and Canada. In addition, Mr. Neels served as Guidant’s Vice President, Global Marketing, Vascular Intervention, from 1996 to 2000 and as Guidant’s General Manager, Germany and Central Europe, from 1994 to 1996. Mr. Neels has a business engineering degree from the University of Leuven in Belgium and an M.B.A. from the Stanford University Graduate School of Business